The phase 3 SUCCESSOR-2 trial showed that adding mezigdomide, an oral CELMoD, to carfilzomib and dexamethasone significantly improved outcomes for patients with relapsed or refractory multiple myeloma.
The triplet regimen doubled median progression-free survival to 18.0 months compared with 8.3 months for carfilzomib and dexamethasone alone, reducing the risk of disease progression or death by 52%. The overall response rate reached 80.2% versus 53.4%, while complete response rates were 60.1% and 8.9%, respectively. Time to next disease progression was also extended to 23.6 months compared with 13.0 months.
The study enrolled heavily pretreated patients, most of whom had prior exposure to lenalidomide and anti-CD38 therapies. While the mezigdomide regimen was associated with frequent grade 3/4 adverse events, including neutropenia, thrombocytopenia, and anemia, investigators reported that side effects were generally manageable.
The findings support mezigdomide-based therapy as a potential new standard of care in this setting.